Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TACR3 | P29371 | 1/20 | 0.33 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.33 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21777432 | 1.00 | LMNA (0.34) | LMNATACR3TEAD1TEAD3PKM | |
| SCHEMBL21783764 | 0.79 | LMNA (0.30) | LMNA | |
| SCHEMBL21783720 | 0.79 | NR1H2 (0.42) | PKM | |
| SCHEMBL2875617 | 0.77 | SLC6A1 (0.39) | TACR3 | |
| SCHEMBL2874098 | 0.77 | SLC6A1 (0.39) | TACR3 | |
| SCHEMBL2874106 | 0.77 | SLC6A1 (0.39) | TACR3 | |
| SCHEMBL526440 | 0.74 | — | — | |
| SCHEMBL26091064 | 0.74 | TACR3 (0.37) | LMNATACR3TEAD1TEAD3 | |
| SCHEMBL26091805 | 0.74 | TACR3 (0.37) | LMNATACR3TEAD1TEAD3 | |
| SCHEMBL26091072 | 0.74 | TACR3 (0.37) | LMNATACR3TEAD1TEAD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242524-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230219949-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230219947-A1 | INHIBITORS OF AV ß6 INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2023-07-13 | — | — | US | disclosed |
| EP-3844162-A1 | INHIBITORS OF av beta6 INTEGRIN | Morphic Therapeutic, Inc. (US) | 2021-07-07 | — | — | EP | disclosed |
| WO-2020081154-A1 | INHIBITORS OF ανβ6 INTEGRIN | MORPHIC THERAPEUTIC, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219947-A1 | INHIBITORS OF AV ß6 INTEGRIN | ITGB6, ITGA6, GP6 | LMNA 3166/4885TACR3 2406/4885TEAD1 4617/4885 |
| US-20230242524-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | LMNA 2000/4885TACR3 2924/4885TEAD1 4032/4885 |
| US-20230219949-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | LMNA 2000/4885TACR3 2924/4885TEAD1 4032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.